Certified by Founder
Lodge
Dispatch Bio
start up
- 24/07/2025
- Series A
- Undisclosed Amount
Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific viral vector, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers.
- Industry Biotechnology Research
- Website https://dispatchbio.com/
- LinkedIn https://www.linkedin.com/company/dispatch-bio/
SetSale | $2,000,000 | (Mar 19, 2026)
Raven.io | $20,000,000 | (Mar 19, 2026)
Manifold Security | $8,000,000 | (Mar 19, 2026)
Beautiful.ai | $45,000,000 | (Mar 19, 2026)
xmemory | $4,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)
Obin AI | $7,000,000 | (Mar 19, 2026)
Multiply(US) | $9,500,000 | (Mar 19, 2026)
Respan (formerly Keywords AI) | $5,000,000 | (Mar 19, 2026)
Homaio | $4,135,744 | (Mar 19, 2026)
Foresight(UK) | $25,000,000 | (Mar 19, 2026)
VerbaFlo.AI | $7,000,000 | (Mar 18, 2026)